Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accretion NutravedaBOM:544694 21 EV-to-FCF is -8.69 as of Aug. 01, 2026. GuruFocus rates BOM:544694 with a GF Score™ of 21/100. The stock has 3 warning signs investors should review. Among 570 Drug Manufacturers companies, Accretion Nutraveda ranks worse than 175438.42% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Accretion Nutraveda's Enterprise Value is ₹2,085.3 Mil.
Accretion Nutraveda's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-240.1 Mil. Therefore, Accretion Nutraveda's EV-to-FCF for today is -8.69.
The historical rank and industry rank for Accretion Nutraveda's EV-to-FCF or its related term are showing as below:
BOM:544694'
s EV-to-FCF Range Over the Past 10 Years
Min: -47 Med: -6.17 Max: -4.57
Current: -8.38
During the past 4 years, the highest EV-to-FCF of Accretion Nutraveda was -4.57. The lowest was -47.00. And the median was -6.17.
BOM:544694's EV-to-FCF is ranked worse than 100% of 570
companies
in the Drug Manufacturers industry
Industry Median: 20.645
vs BOM:544694: -8.38
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Accretion Nutraveda's PE Ratio (TTM) for today is calculated as:
Accretion Nutraveda's share price for today is ₹283.95.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Accretion Nutraveda's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹7.752.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Accretion Nutraveda EV-to-FCF Related Terms
Accretion Nutraveda EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Accretion Nutraveda's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accretion Nutraveda EV-to-FCF Chart
Accretion Nutraveda Annual Data
Trend
Mar23
Mar24
Mar25
Mar26
EV-to-FCF
0.00
0.00
0.00
-6.39
Accretion Nutraveda Semi-Annual Data
Mar23
Mar24
Mar25
Sep25
Mar26
EV-to-FCF
0.00
0.00
0.00
0.00
-6.39
BOM:544694 vs ZTS: EV-to-FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Accretion Nutraveda's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accretion Nutraveda EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Accretion Nutraveda's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Accretion Nutraveda's EV-to-FCF falls into.
Accretion Nutraveda's current Enterprise Value is ₹2,085.3 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Accretion Nutraveda's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-240.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accretion Nutraveda (BOM:544694) has a EV-to-FCF of -8.69 as of Aug. 01, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Accretion Nutraveda and its competitors. According to the industry distribution chart, Accretion Nutraveda ranks #999999 out of 570 companies in the Drug Manufacturers industry.
Is Accretion Nutraveda's EV-to-FCF too high?
Accretion Nutraveda's current EV-to-FCF is -8.69. Based on the distribution chart, Accretion Nutraveda ranks #999999 out of 570 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Accretion Nutraveda has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Accretion Nutraveda's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Accretion Nutraveda ranks #999999 out of 570 companies for EV-to-FCF. This places Accretion Nutraveda in the lower half of its industry. The industry median EV-to-FCF is 20.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.65, based on 570 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Accretion Nutraveda and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Accretion Nutraveda's current EV-to-FCF is -8.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accretion Nutraveda stock overvalued right now?
Accretion Nutraveda (BOM:544694) has a current EV-to-FCF of -8.69. The current EV-to-FCF is -8.69. Accretion Nutraveda's overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Accretion Nutraveda (BOM:544694), the current EV-to-FCF is -8.69 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Accretion Nutraveda Ltd is engaged in the business of the Manufacturing of Ayurvedic and Nutraceutical products across several dosage forms, including Tablets, Capsules, Oral liquids, Oral Powders, External Preparation and Oils. It is a healthcare focused Company specializing in contract manufacturing, serving domestic as well as export markets in various countries like Sri Lanka, Singapore and the USA. The company offers a diverse range of dosage forms, leveraging both Classical Ayurvedic principles and modern nutraceutical science. Its product portfolio includes Tablets, such as film-coated and chewable varieties, for applications in liver care, gynecological care, bone and joint health, and respiratory support.
21GF Score
Get the complete analysis for BOM:544694
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544694 has been successfully added to your 
